CSN Login
Members Online: 6

Update + Going for Anti PDL1 Trial

shamrocklady's picture
shamrocklady
Posts: 19
Joined: Feb 2014

Hello Everyone!

My dad has been seeing Dr. Sznol at Yale. My Dads scans last week showed "moderate" growth on many of his lung mets, but no new lesions on any other organs including on the brain MRI. I take this as relatively good news. This was after an 8 week period of no treatment, awaiting a trial. Two oncologists gave my dad options for treatment vs wait. Both thought waiting would not hurt overall and would give us a chance to enter a trial for patients with no prior systemic treatment. We were discouraged from IL-2 as a first option due to my dad's cardiac history, but they said it's not completely off the table.

My dad is in the approval process for an anti PDL1 trial. One thing we need is a lung biopsy that still needs to be scheduled. The trial compares MPDL3280a or a combo of MPDL3280a with Avastin to Sutent. So there is 2/3 chance we will get MPDL3280a. If we end up in the Sutent group, and my dad has disease progression he would be allowed to cross over to the combo group (assuming he still meets criteria).  

I'm relieved to have a plan. Though we don't know for sure if we are in yet. I'm also nervous to see how my dad responds to treatment. 

 

Darron's picture
Darron
Posts: 222
Joined: Jun 2013

Ito is an opportunity, I say go for it!

dancnbear1
Posts: 47
Joined: Dec 2013

I am in the nivolumab and ipilimimab trial which requires no previous treatments other than surgery. You may also want to look at that. Good luck

 

db

GSRon's picture
GSRon
Posts: 1253
Joined: Jan 2013

In case you missed my other posting... you may wish to check out this video... pretty easy to understand most of it...

http://www.scientificamerican.com/article/wolchok-video-who-knew-cancer-has-an-off-switch-video/?WT.mc_id=SA_SA_20140415=

Ron

foxhd's picture
foxhd
Posts: 1920
Joined: Oct 2011

you got your dad to Yale for treatment.

shamrocklady's picture
shamrocklady
Posts: 19
Joined: Feb 2014

Ron-Nope, I hadn't seen video this yet. It was such a great overview of the field, the progress and most importantly the HOPE of immunotherapy, and will be great to show my dad. I've been doing overtime researching and learning about RCC. My dad only wants the Cliffs notes!

Funny, I checked to see how recent this video/article was published and I was thinking May 1, 2014 VERY recent. Then I thought, wait it's not even May yet!

shamrocklady's picture
shamrocklady
Posts: 19
Joined: Feb 2014

Hey DB,

I originally was looking for a Nivo trial since hearing so many great stories and data from various sources. I did ask about Nivo trials to the oncologist, but there weren't any available to us at the time and now looking at the nivo + ipi trial you mention (if I am looking at the correct one) it sounds like it's not recruiting any new patients.

Thus far the data on MPDL3280a show promise like Nivo, but with possibly fewer side effects. Since it targets the PD1 Ligand, it is suspected that it works best with tumors that express more PDL1. Of course we don't know upfront which patients have greater PDL1 expression. I think this trial is developing a technique to assess that, but we won't get that information back.

I hope this trial offers enough for my dad to make it to the day when some of these immunotherapies, and possibly combos are approved for kidney cancer. From the opinions of two oncologists we saw, they believe Nivo could be approved within the next year for melanoma and even NSCLC, but a while longer for RCC. That seems frustrating! 

NanoSecond's picture
NanoSecond
Posts: 531
Joined: Oct 2012

I think you are correct about the Nivo+Ipi trials being closed to mRCC patients.  In fact BMS (Bristol-Myers Squibb, the manufacturer of both of these drugs) is pretty much excluding RCC patients from many of their new trials these days.

But the good news is that BMS now has lots of competitors (with even more on the way).  These other companies are still recruiting renal cancer patients so just keep looking.

I was very fortunate to be admitted into an anti-PDL1 clinical trial of a drug made by EMD Serono.  This is the American-based arm of Merck.

I only started earlier this month but I have had two infusions so far. It is too early to say how well (or if) it is working but I am quite optimistic that it is.

Any immune-based clinical trial is well worth the effort to get into.  These drugs - or some combination of them - represent the future for all of us.

Finally, although Nivo may not be approved for renal cancer if it is approved for any other kind of cancer you will still be able to obtain it off-label.  So lets hope it happens sooner than later.

GSRon's picture
GSRon
Posts: 1253
Joined: Jan 2013

Yes, those quirky scientists.. predicting the future again..!  I take it this is the May issue.. but at least we know it is recent... funny...  I posted that link in a bunch of spots..  My take is that this is one of the best videos out there right now...  Easy to understand and timely for sure..!!  I am betting that Neil gets good results...

Ron

thaxter's picture
thaxter
Posts: 72
Joined: Jan 2014

When I asked about Nivo being approved next year, he said he thought it might be even earlier than that.

shamrocklady's picture
shamrocklady
Posts: 19
Joined: Feb 2014

Hi Thaxter,

Didn't see your comment until now. I do hope you are right about the Nivo coming out sooner rather than later. So many great drugs for RCC seem to be on the horizon, just not always easy to get your hands on the right treatment! :)

shamrocklady's picture
shamrocklady
Posts: 19
Joined: Feb 2014

Today my father was accepted into the trial and randomized to the MPDL3280a group. He starts infusion tomorrow. Nervous but excited to finally begin.

MPDL3280a definitely shows some good results with PLD1 postive tumors. Genentech the company conducting the trial has proprietary tests to determine PDL1 expression, but we never get to know the results. Bummer.

I am happy to have my dad start in this group since prior trials show it to be better tolerated/fewer side effects and may offer some real hope in a small portion of patients.  If my dad's disease progresses in this group he may have the option to move to the MPDL3280a + Avastin (bevacizumab) combo group.

I'll keep updates with my dad's response to MPDL3280.... Fingers crossed!

NanoSecond's picture
NanoSecond
Posts: 531
Joined: Oct 2012

Shamrock.  Although it is true that tumors expressing PDL1 will generally respond better than those that are negative it is not quite so straightforward.  Many negative PDL1 tumors have been shown to respond as well.  The speculation is that the anti-PDL1 drug may help turn those negative expressing tumors positive.  So don't worry.

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network